These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36237446)

  • 21. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe BG; Högberg T; Glimelius B; Schmidt M; Wernstedt L; Hansen O; Sörensen BT; Räisänen I; van Oosterom AT; de Bruijn KM
    Cancer; 1994 Jan; 73(2):445-54. PubMed ID: 8293412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nausea and vomiting and cancer patients' quality of life: a discussion of Professor Selby's paper.
    Lindley CM; Hirsch JD
    Br J Cancer Suppl; 1992 Dec; 19():S26-9. PubMed ID: 1467197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Opin Pharmacother; 2016 Aug; 17(12):1623-9. PubMed ID: 27322893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
    Plosker GL; Milne RJ
    Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
    Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
    Nakashima K; Murakami H; Yokoyama K; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Nishiyama F; Kikugawa M; Kaneko M; Iwamoto Y; Koizumi S; Mori K; Isobe T; Takahashi T
    Jpn J Clin Oncol; 2017 Sep; 47(9):840-843. PubMed ID: 28633504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glutamate Receptors in the Central Nucleus of the Amygdala Mediate Cisplatin-Induced Malaise and Energy Balance Dysregulation through Direct Hindbrain Projections.
    Alhadeff AL; Holland RA; Nelson A; Grill HJ; De Jonghe BC
    J Neurosci; 2015 Aug; 35(31):11094-104. PubMed ID: 26245970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
    Yoshiya N; Kodama S; Aoki Y; Takahashi T; Honma S; Endo M; Tokunaga A; Takeuchi Y; Hanaoka J; Maruhashi T; Oshima T; Tanaka K; Furue H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1141-7. PubMed ID: 9239168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Yabushita K; Nezuka H; Kinami S; Kadoya N; Takai Y; Tsukioka Y; Ohyama S; Tsuji K; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nausea still the poor relation in antiemetic therapy? The impact on cancer patients' quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster.
    Pirri C; Bayliss E; Trotter J; Olver IN; Katris P; Drummond P; Bennett R
    Support Care Cancer; 2013 Mar; 21(3):735-48. PubMed ID: 22976921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.
    Einhorn LH; Brames MJ; Dreicer R; Nichols CR; Cullen MT; Bubalo J
    Support Care Cancer; 2007 Nov; 15(11):1293-1300. PubMed ID: 17436025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors that influence the antiemetic activity of metoclopramide to cisplatin based chemotherapy.
    Tsavaris N; Mylonakis N; Bacoyiannis C; Kosmas C; Kalergis G; Iakovidis V; Tzaninis D; Kosmidis P
    Oncol Rep; 1998; 5(5):1147-55. PubMed ID: 9683826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of granisetron plus dexamethasone versus an antiemetic cocktail containing midazolam and diphenhydramine for chemotherapy induced nausea and vomiting in children.
    Emir S; Erturgut P; Vidinlisan S
    Indian J Med Paediatr Oncol; 2013 Oct; 34(4):270-3. PubMed ID: 24604956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy-induced nausea and vomiting. Easing patients' fear and discomfort with effective antiemetic regimens.
    Bilgrami S; Fallon BG
    Postgrad Med; 1993 Oct; 94(5):55-8, 62-4. PubMed ID: 8415336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey.
    Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V
    Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of chemotherapy-induced nausea and vomiting.
    Inrhaoun H; Kullmann T; Elghissassi I; Mrabti H; Errihani H
    J Gastrointest Cancer; 2012 Dec; 43(4):541-6. PubMed ID: 22733566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
    J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694).
    Reynolds DJ; Barber NA; Grahame-Smith DG; Leslie RA
    Brain Res; 1991 Nov; 565(2):231-6. PubMed ID: 1668810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.
    Abunahlah N; Sancar M; Dane F; Özyavuz MK
    Int J Clin Pharm; 2016 Dec; 38(6):1464-1476. PubMed ID: 27796777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.